Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study To Evaluate The Efficacy, Safety, And Tolerability Of Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine
NCT05416476 is registered in ClinicalTrials.gov with Second Affiliated Hospital, Zhejiang University, School of Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study To Evaluate The Efficacy, Safety, And Tolerability Of Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- October 30, 2023
- Completion date
- December 31, 2025
- Enrollment
- 288 (estimated)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.